戊巴比妥输注治疗儿童难治性及超难治性癫痫持续状态的结果
该回顾性图表综述纳入2003至2016年接受戊巴比妥输注治疗的0-17岁癫痫持续状态患儿40例,评估死亡、出院时新医疗技术辅助需求及基于儿科脑功能分类(PCPC)评分的功能神经预后。院内死亡率为30%(12/40);存活者中21%(6/28)恢复至基线PCPC,半数(14/28)出院时PCPC下降≥2个等级,25%(7/28)需气管切开、27%(7/26)需新置胃造瘘。单因素分析中病因(p=0.015)、入院时PCPC(p=0.0006)、新气管切开(p=0.012)和新胃造瘘(p=0.012)与PCPC升高≥2个等级相关;校正入院PCPC的多因素logistic回归后均未保持统计学显著性。长期随访中36%(8/22)患儿PCPC较出院时改善,23%(5/22)恶化(包括3例额外死亡)。
要点
- 院内死亡率30%(12/40),存活者中仅21%(6/28)出院时恢复至基线PCPC,半数(14/28)PCPC下降≥2个等级。
- 存活者中25%(7/28)需新气管切开、27%(7/26)需新置胃造瘘,出院时多数新发癫痫持续状态患者仍有发作。
- 单因素分析中病因(p=0.015)、入院时PCPC(p=0.0006)、新气管切开(p=0.012)、新胃造瘘(p=0.012)与PCPC下降≥2个等级相关,但校正入院PCPC后均未保持统计学显著性。
- 戊巴比妥输注时间(p=0.005)和住院时间(p=0.056)在神经功能显著下降的患者中更长。
- 长期随访中36%(8/22)患儿PCPC较出院时改善,23%(5/22)恶化包括3例额外死亡;尽管戊巴比妥输注时间长,仍有存活且神经功能预后良好的病例。
适用人群与场景
- 0-17岁儿童,2003至2016年因癫痫持续状态接受戊巴比妥输注治疗。
研究设计与关键结果
- 回顾性图表综述,纳入40例0-17岁接受戊巴比妥输注治疗的癫痫持续状态患儿。
- 院内死亡率30%(12/40)。
- 存活者中21%(6/28)恢复至基线PCPC,半数(14/28)出院时PCPC下降≥2个等级。
- 存活者中25%(7/28)需气管切开,27%(7/26)需新置胃造瘘。
- 出院时多数新发癫痫持续状态患者仍有发作,多数已知癫痫患者恢复至基线发作频率。
- 单因素分析:病因(p=0.015)、入院时PCPC(p=0.0006)、新气管切开(p=0.012)、新胃造瘘(p=0.012)与PCPC升高≥2个等级相关;戊巴比妥输注时间(p=0.005)和住院时间(p=0.056)在神经功能显著下降患者中更长。
- 校正入院PCPC的多因素logistic回归模型中,上述变量均未保持统计学显著性。
- 长期随访:36%(8/22)患儿PCPC较出院时改善,23%(5/22)恶化包括3例额外死亡。
证据类型、等级与局限
- 证据类型:回顾性图表综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管戊巴比妥输注时间长,仍存在存活且神经功能预后良好的病例。
- 该人群死亡率高,多数患儿出院时存在一定程度残疾。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Functional neurologic outcome for children with refractory and super-refractory status epilepticus has not been well defined.
METHODS: Retrospective chart review including children age 0-17 years who received pentobarbital infusion from 2003 to 2016 for status epilepticus. Outcomes were defined in terms of mortality, need for new medical technology assistance at hospital discharge and functional neurologic outcome determined by pediatric cerebral performance category score (PCPC). Potential patient characteristics associated with functional neurologic outcome including age, sex, ethnicity, etiology of the status epilepticus, and duration of pentobarbital infusion were evaluated.
RESULTS: Forty children met inclusion criteria. In-hospital mortality was 30% (12/40). Of survivors, 21% (6/28) returned to baseline PCPC while half (14/28) declined in function ≥ 2 PCPC categories at hospital discharge. 25% (7/28) of survivors required tracheostomy and 27% (7/26) required new gastrostomy. Seizures persisted at discharge for most patients with new onset status epilepticus while the majority of patients with known epilepsy returned to baseline seizure frequency. Etiology (p = 0.015), PCPC at admission (p = 0.0006), new tracheostomy (p = 0.012), and new gastrostomy tube (p = 0.012) were associated with increase in PCPC score ≥ 2 categories in univariable analysis. Duration of pentobarbital infusion (p = 0.005) and length of hospital stay (p = 0.056) were longer in patients who demonstrated significant decline in neurologic function. None of these variables maintained statistical significance when multiple logistic regression model adjusting for PCPC score at admission was applied. At long-term follow-up, 36% (8/22) of children demonstrated improvement in PCPC compared to discharge and 23% (5/22) showed deterioration including three additional deaths.
CONCLUSIONS: Mortality in this population was high. The majority of children experienced some degree of disability at discharge. Despite prolonged pentobarbital infusion, there were cases of survival with good neurologic outcome.
参考来源
- Erklauer J, Graf J, McPherson M, et al. Outcomes in Children Treated with Pentobarbital Infusion for Refractory and Super-Refractory Status Epilepticus. Neurocrit Care. 2018. PMID: 29582225. doi:10.1007/s12028-018-0513-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。